AstraZeneca announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology. The agreements include two of AstraZeneca’s potential new medicines for dermatitis and psoriasis, allowing the Company to further simplify and sharpen focus on innovative new medicines in the main therapy areas.
Global Technology Centre, Chennai is being established to provide high quality, scalable, cost effective IT services to the AstraZeneca global IT community. With a large pool of highly talented IT staff joining the centre in 2015, the centre will be very strategic in enabling AstraZeneca IT to achieve its overall objectives. The leadership team of Chennai GTC (consisting of the AstraZeneca Chennai Site Lead, Tower Leads and Business Performance Lead) will focus on enabling the workforce to meet global organisational objectives of AstraZeneca IT - including ensuring high levels of service quality and delivery, as well as creating a Great Place to Work at AstraZeneca Chennai. The Business Performance lead for Chennai GTC will be accountable to develop the strategy and measures to enable the Chennai centre to achieve its objectives in terms of quality, speed, efficiency, and service levels.
Post: Business Performance Lead
AstraZeneca announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca.
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC). AstraZeneca acquired exclusive worldwide rights to selumetinib from Array BioPharma Inc. in 2003.
AstraZeneca has fulfilled the deal of the core respiratory business of Takeda Pharmaceutical Company Limited. The agreement, announced in December 2015. Agreement includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca marketed Daliresp in the US in the first quarter of 2015.
AstraZeneca announced that it has handover global rights of Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement,
AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending the approval of a new antibiotic, CAZ AVI 2g/0.5g powder.
AstraZeneca announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA)in December 2015, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of hyperuricemia associated with uncontrolled gout.
Astrazeneca announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
AstraZeneca and its global biologics research and development arm, MedImmune, announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline.
Copyright © 2008-2019, PharmaTutor Edu Labs
Recent Topics